SKAN

Healthy backlog and strong S&C performance confirm FY guidance

18/08/26 -"SKAN delivered 22.2% net sales growth with a healthy order intake (book to bill ratio at 1.51x for 1H26) and a backlog growing 27.8% compared to the end of last year to CHF 442.3m. The configuration ..."

PDF page sample
Pages
58
Language
English
Published on
18/08/26
Download
You may also be interested by these reports :
18/08/26
Coloplast delivered a mixed Q3 FY26: revenue beat consensus (+1.2%) but EBIT missed (-1%), with the margin declining for a third straight quarter. ...
18/08/26
SKAN delivered 22.2% net sales growth with a healthy order intake (book to bill ratio at 1.51x for 1H26) and a backlog growing 27.8% compared to the ...
13/08/26
Ottobock continues to deliver, with a strong set of results in 1H26. Core revenues grew by +7.7% (organic +6.7%), largely supported by a strong EMEA ...
12/08/26
Demant reported better-than-expected Q2 results, with robust top-line growth across all segments. Profitability rose by double digits in H1, and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO